Hosai
4 minutes ago
Much better to have a smaller, successful phase 2b/3 in the endpoints EMA care most about, in which due to being smaller it's harder to have low p values than a 'proper' phase 3, that also has a fair amount of dropouts in the case of Donnanemab, that can in rare cases kill patients, causes ARIA, shr